Biotech fares better than markets in sell-off U.S. biotech indexes fared slightly better than the broader markets Wednesday as stocks tumbled amid fresh signs of a global economic slowdown and a signal from bond markets...

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...

A University of California Berkeley team has discovered how to boost the efficiency of homology-directed repair (HDR) of genomic cuts made by CRISPR- Cas9 , without disrupting proliferation or other DNA repair mechanisms. By dialing in...

Direct Genomics launched GenoCare Analyzer in China for genome sequencing of drug-resistant HBV infection and circulating tumor DNA. The assay uses single molecule targeted sequencing to read DNA and RNA molecules from blood or tissue...

Caribou Biosciences Inc. and Atlas Venture co-founded Intellia Therapeutics LLC to develop gene and cell therapies based on Caribou's CRISPR genome editing technology. Intellia has exclusive rights to CRISPR IP from a co-inventor of the...

Despite the fact that the therapeutic utility of CRISPR-based approaches has yet to be demonstrated, venture dollars keep flowing into new companies developing the platform. But proof of concept may come faster than expected as...

By all accounts, last week was a banner week on the venture side. A total of $175.4 million was raised by private biotechs, which far exceeded the industry’s average of about $100 million per week...

Cellectis granted SHP a worldwide, non-exclusive license to use Cellectis' site-directed genome engineering technologies to develop genetically engineered cells that produce gene-activated biopharmaceuticals. Further terms were not disclosed. Cellectis SA , Romainville, France Shire Pharmaceuticals Group...